Early-Stage Pharmaceutical Marketing Budgets

Preparing for Product Launch

Early-Stage Pharmaceutical Marketing Budgets


With spending data for the commercialization of 14 brands, this report analyzes early-stage pharmaceutical marketing budgets and early-phase resource allocation for products of all sizes — including niche products with modest budgets, mid-level products balancing their expenditures, and larger brands with blockbuster hopes. Each brand's data are presented in product profile format. The profiles break down each brand's commercialization budgets into 10 spending categories — providing our clients with more detailed budgets than were included in previous Cutting Edge Information reports or can be found in our competitors' reports today.

  • Description
  • Additional information


Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch examines the commercialization budgets of 14 brands from the pre-clinical stage of development through Phase 2 clinical trials. The report is organized into 14 chapters, each of which is a profile of a different brand. The 14 brands are developed and marketed by a variety of companies that range from the industry’s largest pharmaceutical and biotechnology companies to small biopharmas that have yet to market their first product. Furthermore, the brands have a variety of commercial expectations. Throughout the report, drugs are often referred to as blockbusters, mid-level products, and small or niche brands.

Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch

  • Publication Date: March 2007
  • Pages: 322
  • Metrics: 780+
  • Charts and Metrics: 298

Report Structure:

  • Commercial Profile
  • Clinical Profile
  • Early-Stage Commercialization
Report Features

The information contained in this report was gathered from brand managers and directors; marketing, brand, and project team members; and vice presidents of marketing and R&D at several companies. The report analyzes commercialization budget allocations for 14 brands with a broad spectrum of peak annual sales expectations, commercial and clinical profiles, and promotional infrastructures.

Reason to Buy

Some project and brand teams make a critical mistake early in their drugs’ development lifecycles – they fail to adequately prepare the market for their products. Early-stage commercialization and market preparation deficiencies often are the result of insufficient funding rather than poor planning. Don’t allow your product’s commercial potential to falter. Use Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch to bolster your case for larger commercial budgets and to benchmark your marketing spends in pre-clinical development, Phase I and Phase II.

Target Audience

The report is designed to help the following biopharmaceutical executives' decision making around early stage product commercialization:
– Brand/product directors and managers
– Franchise area heads and senior directors
– Strategic planning directors
– Marketing directors and managers
– Brand advertising and promotions directors and managers

Chapter Example

Project team leaders and strategic marketers consulted for this research point to some very specific reasons that these spending patterns emerge. Early in a drug’s lifecycle, project and brand teams’ primary objectives are to start outlining the competitive landscape, to identify unmet needs and to spot potential problem areas that could inhibit a drug’s commercial development in the years ahead. Marketers tackle these challenges with market research, which is one of the best tools brand teams have at their disposal early on. Market research also plays a key role in the development of the first version(s) of target product profiles, which most brand teams complete or nearly complete by the end of Phase 1.